Naveris Nabs $33.4M Series A Round Expansion to Further Commercialize Virus-Related Cancer Tests
The new funding brings the total investment in the firm to $51 million, which Naveris will use for commercialization of its NavDx assay.
The company plans to publish new data on clinical sensitivity and specificity and has initiated multiple studies investigating new use cases.
Yourgene Health to Distribute Take2 Health Nasopharyngeal Cancer Screening Test in Taiwan
Yourgene's Taipei subsidiary will promote the Take2 Prophecy test in Taiwan and will establish a clinical network for the collection of patient blood samples.
HPV Head and Neck Cancer Recurrence Test Data Adds Validation as Naveris Ramps Clinical Launch
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
Cancer Diagnostics Firm Lucence Raises $20M
The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.